In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer

In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer

ReachMD Healthcare Image

Listen in for the latest data in HER2-positive advanced gastric/GEJ cancer, presented at the 2023 World Congress on GI Cancer in Barcelona, Spain.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Gastric and gastroesophageal junction cancers are the third most common cause of cancer deaths globally. In this Chairman’s Perspective, Dr. John Marshall breaks down the latest data from the 2023 World Congress on GI Cancer in Barcelona, Spain, so you can more effectively treat your patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    John L. Marshall, MD
    Professor of Medicine and Oncology
    Lombardi Comprehensive Cancer Center
    Georgetown University
    Washington, DC

    Consulting Fees: AstraZeneca, Bayer Corporation, Caris, Merck & Co., Inc., Pfizer, Seagen, Taiho Oncology.
    Employee of an ineligible company: Indivumed

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Sara Fagerlie has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Collaborate with pathologists to appreciate the clinical implications of HER2 heterogeneity
    • Collaboratively employ biomarker-based testing to improve personalization of therapy in advanced gastric and gastroesophageal junction (GEJ) cancer
    • Compare and contrast clinical trial successes and failures in the second-line treatment of advanced HER2-positive gastric/GEJ cancer
    • Identify patients eligible for HER2-directed therapies in the second-line treatment of advanced HER2-positive gastric/GEJ cancer, which offer both improved survival outcomes and quality of life
    • Assess the current and potential future standard of care in the second-line setting of advanced HER2-positive gastric/GEJ cancer, including HER2-low amplification
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists and pathologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Daiichi Sankyo, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free